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Objective. Systemic lupus erythematosus (SLE) is
a systemic autoimmune syndrome associated with organ
damage and an elevated risk of cardiovascular disease
resulting from activation of both innate and adaptive
immune pathways. Recently, increased activation of the
inflammasome machinery in SLE has been described.
Using the mouse model of pristane-induced lupus, we
undertook this study to explore whether caspase 1, the
central enzyme of the inflammasome, plays a role in the
development of SLE and its associated vascular dys-
function.
Methods. Eight-week-old wild-type (WT) or
caspase 1–/– mice were injected intraperitoneally with
phosphate buffered saline or pristane. Six months after
injection, mice were euthanized, and the development of
a lupus phenotype and vascular dysfunction was as-
sessed.
Results. While WT mice exposed to pristane de-
veloped autoantibodies and a strong type I interferon
response, mice lacking caspase 1 were significantly
protected against these features as well as against
pristane-induced vascular dysfunction. Further, the de-
velopment of immune complex glomerulonephritis,
which was prominent after pristane exposure in WT
mice, was significantly abrogated in caspase 1–/– mice.
Conclusion. These results indicate that caspase 1
is an essential component in the development of lupus
and its associated vascular dysfunction and that it may
play an important role in the cross-talk between environ-
mental exposures and autoimmunity development, thus
identifying a novel pathway for therapeutic targeting.
Systemic lupus erythematosus (SLE) is a systemic
autoimmune syndrome with severe clinical manifesta-
tions and enhanced mortality rates triggered by
immune-mediated organ damage and a significant in-
crease in cardiovascular (CV) risk due to premature
atherosclerosis (1). An important contributor to devel-
opment of both SLE and its associated increased CV risk
is the up-regulation of type I interferon (IFN) responses,
which influence both innate and adaptive immune pro-
cesses and promote vascular damage (2–4).
Tetramethylpentadecane, commonly known as
pristane, is a naturally occurring hydrocarbon oil that
can induce chronic inflammation when introduced into
the peritoneal cavity. Pristane injection is recognized as
a robust model of lupus development, replicating nu-
merous human manifestations, including autoantibody
generation, arthritis, and severe glomerulonephritis (5).
Further, the inflammatory response to pristane results in
a strong up-regulation of type I IFNs through Toll-like
receptor 7 (TLR-7) and IFN regulatory factor 5 (IRF-5)
activation, contributing to a lupus-like phenotype (5,6).
Indeed, lack of the type I IFN receptor results in limited
TLR-7 expression, decreased autoantibody synthesis,
and hampered recruitment of inflammatory monocytes
(Ly-6Chigh) due to decreased synthesis of the chemokine
CCL2/monocyte chemoattractant protein 1 (MCP-1)
(7,8). Thus, this model replicates many phenotypic and
functional abnormalities of human SLE and has proven
very useful in identifying putative pathogenic mecha-
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nisms and environmental triggers in this disease in a type
I IFN–dependent system.
The inflammasome is a multimolecular complex
consisting of platform molecules, scaffolds, and caspase
1, the enzyme responsible for processing of
interleukin-1 (IL-1) and IL-18 to their active forms
(9). Activation of the inflammasome results from detec-
tion of environmental danger signals, including intracell-
ular bacteria and cholesterol crystals (9). A role of the
inflammasome in SLE pathogenesis and organ damage
has been recently proposed. Activation of the NLRP3
inflammasome by neutrophil extracellular traps (NETs),
chromatin structures released by neutrophils as a form
of cell death termed “NETosis,” and associated LL-37 is
enhanced in lupus macrophages (10). Further, immune
complexes formed by lupus-associated autoantigens
(double-stranded DNA [dsDNA] and RNP) and their
respective autoantibodies can activate the inflam-
masome machinery in monocytes (11,12). Similar acti-
vation of the inflammasome was described following
exposure to IFN in endothelial progenitor cells (EPCs)
in human and murine SLE (4). Because these cells are
considered key in promoting vascular repair following
an insult to the endothelium, inflammasome activation
in this system may promote the enhanced CV risk in
patients with SLE (4). However, it remains unclear if the
inflammasome or its components serve as crucial medi-
ators of autoimmune responses and organ damage in
vivo in SLE. Thus, we used the pristane-induced lupus
model to examine whether the central enzyme of the
inflammasome, caspase 1, was required for lupus devel-
opment and severity.
MATERIALS AND METHODS
Mice. All animal protocols were reviewed and ap-
proved by the University of Michigan’s committee on use and
care of animals. Breeding pairs of caspase 1–/– mice were
initially obtained from Dr. R. A. Flavell (Yale University, New
Haven, CT) and backcrossed onto the BALB/c background for
at least 8 generations. Wild-type (WT) BALB/c and C57BL/6
mice were obtained from The Jackson Laboratory. Breeding
pairs of caspase 1–/– mice on a C57BL/6 background were
obtained from Dr. Gabriel Nunez (University of Michigan,
Ann Arbor, MI). Mice were bred at the University of Michi-
gan. For lupus induction, 8-week-old mice were administered a
single 0.5-ml intraperitoneal (IP) injection of phosphate buff-
ered saline (PBS) (as a control) or pristane (Sigma-Aldrich)
and were euthanized 6 months postinjection for the studies.
EPC quantification and assessment of differentiation.
Bone marrow mononuclear cells were quantified by flow
cytometry as previously described (2). Briefly, EPCs were
defined as CD34CD309 cells in the lineage-negative
(CD19–, CD3–, and CD45–) gate. This number was then
extrapolated to calculate the percentage of EPCs in the live
cell gate and is presented as the total number of EPCs/106
isolated bone marrow cells. The following antibodies were
used: biotin-conjugated anti-CD19 (eBioscience), biotin-
conjugated anti-CD3e (eBioscience), phycoerythrin (PE)–
Cy5–conjugated anti-CD45 (BioLegend), fluorescein isothio-
cyanate (FITC)–conjugated anti-CD34 (eBioscience),
allophycocyanin-conjugated anti-CD309 (eBioscience), and
Pacific Blue–conjugated anti–annexin V (BioLegend). To de-
tect anti-CD19 and anti-CD3e, a streptavidin–PE–Cy5–
conjugated secondary antibody was used (BioLegend). Flow
cytometry was performed using a CyAn ADP Analyzer (Beck-
man Coulter).
Assessment of the capacity of bone marrow–derived
EPCs to differentiate into mature endothelial cells (ECs) was
performed as previously described (4). Briefly, bone marrow
mononuclear cells were plated onto fibronectin-coated plates
(Becton Dickinson) at a density of 1  106 cells/cm2 in
EGM-2 BulletKit media (Lonza) supplemented with 5% heat-
inactivated fetal bovine serum. After 7 days in culture, live cells
were incubated for 3 hours with FITC-conjugated Bandeiraea
(Griffonia) simplicifolia lectin 1 (Vector) and Texas Red–
conjugated diacetylated low-density lipoprotein (Di-Ac-LDL;
Biomedical Technologies). To assess EC morphology and ex-
pression of mature endothelial markers, cells were analyzed
using fluorescence microscopy as described elsewhere (4). A
total of 3 random fields of view were acquired for every
triplicate well; images were analyzed using the CellC program
(https://sites.
google.com/site/cellsoftware/download) to quantify mature
ECs, which were considered those that costained with Ban-
deiraea (Griffonia) simplicifolia lectin 1 and Ac-LDL.
Assessment of endothelium-dependent vasorelaxation.
Assessment of endothelium-dependent vasorelaxation was
performed as previously reported (13). Briefly, following eu-
thanasia, thoracic aortas were excised and cleaned. The endo-
thelium was left intact, and 2-mm aortic rings were mounted in
a myograph system (Danish Myo Technology) and bathed with
aerated (95% O2/5% CO2) physiologic salt solution. Aortic
rings were set at 700 mg of passive tension, equilibrated for 1
hour, with buffer change every 20 minutes. The vessels were
contracted twice with physiologic salt solution containing 100
mM potassium chloride prior to performing contraction/
relaxation measurements. Cumulative concentrations of phen-
ylephrine (10–9–10–5 moles/liter) were added to the bath to
establish a contraction concentration-response curve. A phen-
ylephrine concentration corresponding to 80% of maximum
was added, and contraction was allowed to reach a stable
plateau. Endothelium-dependent relaxation was then assessed
via graded addition of acetylcholine in a cumulative manner.
Characterization of autoantibodies and cytokine syn-
thesis. Total serum IgG, anti-dsDNA, and anti-RNP antibody
levels were quantified by enzyme-linked immunosorbent assay
(ELISA) using commercially available kits (Alpha Diagnostic),
following the manufacturer’s protocols. Plasma cytokine and
chemokine levels were quantified in undiluted plasma samples
using a custom-designed Milliplex assay (EMD Millipore).
IL-18 levels were measured via ELISA (eBioscience).
Proteinuria, renal histopathology, and immune com-
plex deposition scoring. Urine samples were collected prior to
euthanasia and were assessed for total protein with a Bradford
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assay (Bio-Rad), for microalbumin using an Albuwell kit
(Exocell), and for creatinine using a Creatinine Companion kit
(Exocell). Ratios of total protein to creatinine and microalbu-
min to creatinine were calculated to estimate 24-hour urinary
protein excretion.
For glomerular immune complex deposition, frozen
sections were quantified for C3 and IgG deposition as previ-
ously described (13). Briefly, sections were stained with FITC-
conjugated anti-C3 (ICL) and Cy3-conjugated anti-mouse IgG
(Sigma) for 1 hour at 4°C. DNA was visualized using Hoechst
(Invitrogen). Immune complexes were scored in a blinded
manner by 2 independent observers (JMK, JBH). A score on a
scale of 0–3 was assigned for both C3 and IgG deposition
based on intensity of signal, and scores were multiplied by 2 if
the staining diffusely involved the glomeruli. Six glomeruli per
mouse were scored, and the averaged score for each compo-
nent (IgG and C3) was added to create the composite score.
To score glomerular inflammation, paraffin-embedded
cortical sections were sectioned at 3 m thickness. Periodic
acid–Schiff–stained sections were examined and graded by one
of the authors (JBH) in a blinded manner following procedures
previously described by us (13). Briefly, a semiquantitative
scoring system was used to assess 2 different parameters of
activity (mesangial hypercellularity and endocapillary cellular
infiltrate), as follows: 0  no involvement, 0.5  minimal
involvement (10% of a section), 1  mild involvement
(10–30% of a section), 2  moderate involvement (31–60% of
a section), and 3  severe involvement (60% of a section).
An activity index was generated by compiling these scores.
Real-time polymerase chain reaction (PCR). Total
RNA was purified via TriPure (Roche) from 1  106 perito-
neal cells, half of a homogenized spleen, or 1  106 bone
marrow cells isolated on a Histopaque 1083 (Sigma) gradient.
One microgram of RNA was transcribed into complementary
DNA using oligo(dT) and Moloney murine leukemia virus
(Invitrogen) using a MyCycler thermocycler (Bio-Rad).
The following transcripts and primers were used: for
MCP-1, 5-AGGTCCCTGTCATGCTTCTG-3 (forward) and
5-GGATCATCTTGCTGGTGAAT-3 (reverse); for myxovi-
rus (influenza virus) resistance protein 1, 5-GATCCGACTT-
CACTTCCAGATGG-3 (forward) and 5-CATCTCAGTGG-
TAGTCAACCC-3 (reverse); for IRF-7, 5-TGCTGTTTGG-
AGACTGGCTAT-3 (forward) and 5-TCCAAGCTC-CCG-
GCTAAGT-3 (reverse); for IFN-inducible protein 10, 5-
ATCATCCCTGCGAGCCTAT-3 (forward) and 5-ATTCT-
TGCTTCGGCAGTTAC-3 (reverse); for IFN-stimulated
gene 15 (ubiquitin-like modifier), 5-CAGAAGCAGACTCC-
TTAATTC-3 (forward) and 5-AGACCTCATATATGTTG-
CTGTG-3 (reverse); for IFN, 5-AGCGGCTGACTGAAC-
TCAGATTGTA-3 (forward) and 5-GTCACAGTTTTCAG-
CTGTATAGGG-3 (reverse); for -actin, 5-TGGAATCCT-
GTGGCATCCTGAAAC-3 (forward) and 5-TAAAACGC-
AGCTCAGTAACAGTCCG-3 (reverse); for IL-18, 5-ACT-
GTACAACCGCAGTAATACGC-3 (forward) and 5-AGT-
GAACATTACAGATTTATCCC-3 (reverse); for IL-1, 5-
CCCTGCAGCTGGAGAGTGTGGA-3 (forward) and
5-CTGAGCGACCTGTCTTGGCCG-3 (reverse); for
caspase 1, 5-GACTGGGACCCTCAAGTTTT-3 (forward)
and 5-CCAGCAGCAACTTCATTTCT-3 (reverse); and for
NLRP3, 5-ATGCTGCTTCGACATCTCCT-3 (forward) and
5-AACCAATGCGAGATCCTGAC-3 (reverse).
An ABI Prism 7900HT instrument (Applied Biosys-
tems) was used for quantitative real-time PCR analysis. Sam-
ples were normalized to -actin, and the fold change was
expressed as pristane-treated compared to PBS-treated sam-
ples.
Characterization of peritoneal inflammatory infil-
trate. Peritoneal cells were collected by lavage after euthana-
sia. Washed cells were incubated with fluorochrome-labeled
antibodies (anti-CD11b, anti-F4/80, anti-CD11c, anti-CD4,
anti–annexin V, and anti-CD317/PDCA [BioLegend], anti–
Ly-6G, anti–Ly-6C, and anti-CD3e [BD Biosciences], and
anti-CD8a [eBioscience]) and analyzed by flow cytometry.
Neutrophils were defined as Ly-6G/CD11b in the F4/80–
gate, plasmacytoid dendritic cells (PDCs) as CD11cPDCA
in the live cell gate, myeloid DCs as CD11cPDCA– in the live
cell gate, inflammatory monocytes as CD11bLy-6Chigh in the
Ly-6G– gate, and T cells as CD3eCD4 or CD3eCD8.
The final data were expressed as the percentage of cells
positive for the specific marker per 106 cells collected.
Characterization of NETs. Bone marrow neutrophils
were isolated via Percoll gradient based on a previously
published protocol (14). Cells (1.5  105) were adhered onto
poly-L-lysine–coated coverslips at 37°C and then treated over-
night with 40 nM phorbol myristate acetate (PMA). Cells were
washed and stained with murine anti–neutrophil elastase (Ab-
cam) and Hoechst. NETs were visualized via fluorescence
microscopy and counted as previously described by our group
(15). Total cell numbers were determined by the number of
nuclei present per image, and numbers of NETs were deter-
mined by counting the number of elongated DNA structures
costaining with murine anti–neutrophil elastase and Hoechst.
Statistical analysis. The D’Agostino and Pearson om-
nibus normality test was used to evaluate Gaussian distribution
of the data. Analysis of statistical differences between the
means of normally distributed data was evaluated by Student’s
unpaired t-test, and Welch’s correction was added when vari-
ances were statistically significant as judged by an F test to
compare variances. Non-normally distributed data were eval-
uated by a Mann-Whitney test. Linear regression analysis was
used to correlate anti-dsDNA titers with renal inflammation,
and composite histologic scoring was used to correlate IL-18
levels with renal inflammation.
RESULTS
Pristane exposure results in up-regulation of the
inflammasome machinery. Elevated levels of IL-18 and
caspase 1 associated with SLE have been described
(4,16,17), and IL-1 levels are known to be increased in
pristane-injected mice (18). In order to confirm these
findings in the pristane-induced lupus model, real-time
PCR was used to quantify transcripts from splenocytes
isolated from BALB/c mice 6 months after IP pristane
injection. As shown in Table 1, pristane robustly induced
inflammasome-associated transcripts, and a trend to-
ward elevated IL-18 and IL-1 transcript levels was
seen in the spleens of WT mice injected with pristane,
but not in the spleens of caspase 1–/– mice injected with
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pristane. This suggests that the pristane-induced lupus
model replicates the alterations of the inflammasome
described in human SLE in a caspase 1–dependent
manner and that it is a relevant model for studying the
effects of caspase 1 on lupus pathogenesis.
Inflammatory responses to pristane are intact in
WT and caspase 1–/– mice. As pristane-induced lupus
depends on recruitment of inflammatory cells, particu-
larly inflammatory monocytes (19,20), into the perito-
neal cavity, we determined whether a lack of caspase 1
modified inflammatory cell recruitment following
pristane exposure. As shown in Figure 1A, the inflam-
matory response following pristane injection was vigor-
ous in both WT and caspase 1–/– BALB/c mice. Further
analysis showed no difference in PDC, myeloid DC, or
inflammatory monocyte recruitment to the peritoneal
cavity (Figure 1B). An enhanced recruitment of neutro-
phils was observed in caspase 1–/– mice (Figure 1B).
Further, no difference was noted between WT and
caspase 1–/– mice in the number or size of peritoneal
lipogranulomas following pristane exposure (data not
shown). These results indicate that lack of caspase 1
does not significantly alter the recruitment of inflamma-
tory cells into the peritoneal cavity or change the
formation of lipogranulomas, which are considered a
nidus of chronic inflammatory mediators for disease
development (5,21).
Absence of caspase 1 protects against the devel-
opment of lupus autoantibodies. In order to determine
whether lack of caspase 1 is protective in a lupus model,
Table 1. Fold change in levels of splenic inflammatory transcripts 6
months after pristane injection in WT and caspase 1–/– mice*
Gene
WT mice Caspase 1/ mice
Fold change P† Fold change P†
NLRP3 19.70  8.352 0.0020 0.4845  0.6457 0.6753
CASP1 4.964  2.034 0.0456 – –
Il1b 106.4  71.77 0.1418 43.40  37.77 0.4351
Il18 404.8  286.4 0.0813 14.53  6.682 0.3358
* Values are the mean  SEM.
† Calculated by comparison of 	Ct between phosphate buffered
saline–treated mice (7 wild-type [WT] and 11 caspase 1/) and
pristane-treated mice (13 WT and 23 caspase 1/).
Figure 1. BALB/c caspase 1–/– (–/–) mice have intact peritoneal inflammatory responses to pristane (PR) injection but display decreased
autoantibody and inflammatory cytokine synthesis. A and B, Two weeks after pristane or phosphate buffered saline (PBS) injection, peritoneal fluid
was harvested from wild-type (WT) mice (4 injected with PBS, 10 injected with pristane) and caspase 1–/– mice (5 injected with PBS, 11 injected with
pristane). Total cell numbers were counted and are plotted as the number of cells per ml of peritoneal fluid removed (A). Cell populations were
quantified by flow cytometry and are expressed as a percentage of the total cell population when 1  106 total cells are examined (B). C, Antibody
titers in sera from WT BALB/c mice or caspase 1–/– BALB/c mice obtained 6 months after exposure to PBS or pristane were determined by
enzyme-linked immunosorbent assay. Each symbol represents a single mouse. D, Plasma concentrations of interleukin-6 (IL-6) and IL-17 from mice
described in C were quantified in undiluted samples using a custom-designed Milliplex assay. In C and D, there were 6 PBS-treated WT mice, 11
PBS-treated caspase 1–/– mice, 13 pristane-treated WT mice, and 24 pristane-treated caspase 1–/– mice. Bars show the mean  SEM.   P  0.05;
  P  0.01;   P  0.001. NS  not significant; DC  dendritic cell; anti-dsDNA  anti–double-stranded DNA.
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we examined whether autoantibody production was al-
tered 6 months after pristane exposure in caspase 1–/–
mice compared to WT mice. As shown in Figure 1C,
pristane induced a substantial increase in anti-dsDNA
and anti-RNP antibodies in WT BALB/c mice 6 months
postinjection. In contrast, autoantibody production in
caspase 1–/– mice was significantly blunted. Hypergam-
maglobulinemia, manifested by a rise in total IgG fol-
lowing exposure to pristane, was also decreased in
caspase 1–/– mice. Furthermore, levels of circulating
inflammatory cytokines, such as IL-6 and IL-17, were
lower in PBS- and pristane-treated caspase 1–/– mice,
suggesting an overall reduced inflammatory phenotype
(Figure 1D). Unlike studies involving IRF-5–knockout
mice (22), no differences in Th1 versus Th2 cytokine
skewing were observed in WT mice compared to caspase
1–/– mice following pristane exposure (Table 2). Overall,
these results suggest that lack of caspase 1 modifies B
cell responses and levels of proinflammatory cytokines
and leads to decreased autoantibody formation in re-
sponse to pristane.
Absence of caspase 1 decreases type I IFN signa-
tures in pristane-induced lupus. Induction of a type I
IFN response has been reported to play an important
role in the development and severity of human and
murine lupus (3,7,23,24). In the pristane-induced model
of lupus, type I IFN pathways are required for disease
development, as mice lacking the type I IFN receptor,
TLR-7, or IRF-5 do not develop a clinical phenotype
(6,7,20,25). Type I IFN responses were examined in the
spleens and bone marrow of WT and caspase 1–/– mice 2
weeks and 6 months after exposure to pristane. As
shown in Figure 2A, 2 weeks after exposure to pristane,
there were no significant differences in type I IFN
responses between WT and caspase 1–/– mice. In con-
trast, splenocytes and bone marrow cells isolated 6
months after treatment from WT mice, but not from
caspase 1–/– mice, displayed significant up-regulation of
type I IFN–regulated genes when compared to litter-
mates exposed to PBS. This repression of IFN signatures
was not secondary to alterations in signaling through
TLR-7, as exposure to the TLR-7 ligand R848 resulted
in similar up-regulation of type I IFN–regulated genes in
WT and caspase 1–/– mice (Figure 2B).
Further, as an important role has been demon-
strated for inflammatory monocytes in the initiation of
type I IFN responses in the pristane-induced model of
lupus (26), we examined whether differences in IFN
signatures of these cells occurred in pristane-exposed
WT and caspase 1–/– mice. No significant differences
were noted in the IFN signature of peritoneal inflam-
matory cells between WT and caspase 1–/– mice 2 weeks
after exposure to pristane (data not shown). These
results indicate that lack of caspase 1 triggers repression
of type I IFN signatures in pristane-treated mice.
The aberrant clearance of apoptotic debris in
SLE may lead to autoantigen exposure and promotion of
the type I IFN response and autoimmune pathways (27).

























MCP-1/CCL2 36  10.37 174.8 25.86 0.0024 78.36 78.36 124.4  16.1 0.0251 0.0856
MIP-1/CCL3 9.5  5.051 45  10.57 0.0105 1.83 1.273 14.23  2.425 0.0004 0.0009
IP-10/CXCL10 205 49.12 332.8 29.11 0.0393 163.7  25.16 335.8  42.63 0.0007 NS
RANTES/CCL5 18.17 5.474 18.92  3.68 NS 51.09  27.07 63.67  25.35 NS 0.0371
GM-CSF 75.17 18.4 85.00  25.38 NS 53.40  16.45 80.08  25.13 NS NS
IFN 0.6667  0.494 0.6154  0.368 NS 0.8000 0.467 1.292  0.682 NS NS
IL-1 9.000  4.025 4.154  2.189 NS 8.900  3.761 3.167  1.788 NS NS
IL-2 26.83  7.639 19.46  8.883 NS 8.545  4.137 7.875  2.23 NS NS
IL-4 0 0.7692 0.077 NS 0 0 NS NS
IL-5 4.5  2.986 11.23 3.327 NS 9.273 4.083 6.833  2.103 NS NS
IL-10 0 0 NS 11.18 11.18 11.79  9.548 NS NS
IL-12p40 27.33  9.535 57.62  42.07 NS 42.45  11.89 80.21  53.55 NS NS
IL-12p70 5.333  2.894 261.6  229.8 NS 2.545 1.065 11.13  8.632 NS NS
TNF 2.5  1.586 4.615 1.357 NS 4.182 1.536 3.25  0.7 NS NS
* There were 6 phosphate buffered saline (PBS)–treated wild-type (WT) mice, 11 PBS-treated caspase 1/ mice, 13 pristane-treated WT mice, and
24 pristane-treated caspase 1/ mice. Values are the mean  SEM. MCP-1  monocyte chemoattractant protein 1; MIP-1  macrophage
inflammatory protein 1; IP-10  interferon-–inducible protein 10; NS  not significant; GM-CSF  granulocyte–macrophage colony-stimulating
factor; IFN  interferon-; IL-1  interleukin-1; TNF  tumor necrosis factor .
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Pristane exposure induces various forms of cell death,
including NETosis in neutrophils and apoptosis in vari-
ous inflammatory cells in the peritoneal cavity (18).
Therefore, we examined whether the absence of caspase
1 modified cell death responses 2 weeks following
pristane injection. We were unable to detect spontane-
ous NET formation in neutrophils isolated directly from
the peritoneum after pristane exposure. In contrast,
robust NET formation was observed following PMA
stimulation of bone marrow–derived neutrophils from
WT and caspase 1–/– mice, suggesting that caspase 1 does
not influence the NET response (Figure 2C).
In order to evaluate the role of caspase 1 in
pristane-induced apoptosis and pyroptosis (inflamma-
tory cell death), we used annexin V staining of perito-
neal inflammatory cells isolated 2 weeks after pristane
exposure. We detected a significant decrease in annexin
V staining, which recognizes both apoptotic and pyro-
ptotic cells (28), in peritoneal cells isolated from caspase
1–/– mice when compared to WT mice (Figure 2D). This
suggests that cell death following pristane exposure is
abrogated in caspase 1–/– mice. As aberrant cell death is
considered an important phenomenon in modified auto-
antigen externalization, the formation of immune com-
plexes, and the development of enhanced type I IFN
responses (27), our observations suggest that caspase 1
Figure 2. Type I interferon (IFN) signature induced after pristane exposure is abrogated in caspase 1–/– (Casp-1 –/–) mice. A, Shown is the fold
change in mRNA for type I IFN–regulated genes in splenocytes and bone marrow mononuclear cells isolated from BALB/c mice 6 months (top)
or 2 weeks (bottom) after treatment. Following normalization to -actin, comparisons of 	Ct were made for pristane-treated versus PBS-treated
mice. There were 7 PBS-treated WT mice, 11 PBS-treated caspase 1–/– mice, 14 pristane-treated WT mice, and 24 pristane-treated caspase 1–/– mice.
B, Splenocytes from 10-week-old WT BALB/c mice or caspase 1–/– BALB/c mice (n 5 each) were stimulated with R848 for varying periods of time.
Quantification of mRNA for type I IFN–regulated genes was performed as in A. C, Bone marrow neutrophils were isolated from WT or caspase
1–/– mice (n  4 each) and stimulated overnight with 40 nM phorbol myristate acetate. Neutrophil extracellular traps (NETs) were detected by
extracellular colocalization of murine anti–neutrophil elastase and Hoechst. The percentage of NETs is calculated as number of NETting cells/total
number of cells. D, Two weeks after pristane injection, peritoneal inflammatory cells were isolated, stained with annexin V, and analyzed via flow
cytometry. Shown is the number of apoptotic/pyroptotic cells per 100 cells in the live cell gate for each mouse (10 WT mice, 6 caspase 1–/– mice).
Bars show the mean  SEM.   P  0.01;   P  0.001. MCP-1  monocyte chemoattractant protein 1; Mx-1  myxovirus (influenza virus)
resistance protein 1; IRF-7  IFN regulatory factor 7; IP-10  IFN-inducible protein 10; ISG-15  IFN-stimulated gene 15 (see Figure 1 for other
definitions).
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may play an important role in regulating type I IFN
synthesis by modulating cell death pathways.
Absence of caspase 1 decreases markers of CV
risk. The inflammasome has been implicated in inflam-
matory responses in atherosclerotic plaques (29), and
lack of caspase 1 modulates severity of atheroma in
murine models (30). We previously demonstrated that in
vitro inhibition of caspase 1 improves the differentiation
of human lupus EPCs into mature ECs, a phenomenon
that may be important in preventing vascular damage in
this disease (4,31,32). Thus, we examined whether lack
of caspase 1 modified CV parameters in the pristane-
induced model of lupus. Mice in both the BALB/c and
C57BL/6 backgrounds were studied, as lupus models of
various backgrounds display endothelial dysfunction to
varying degrees (33).
Neither exposure to pristane nor absence of
caspase 1 altered the number of bone marrow EPCs, as
assessed by flow cytometry (Figure 3A). However, ab-
sence of caspase 1 significantly abrogated the inhibitory
effects on EPC differentiation induced by pristane (Fig-
ures 3B and C). These observations confirm previous in
vitro findings in human samples and indicate that
caspase 1 is operational in vivo with regard to lupus-
mediated EPC dysfunction. Previously, investigators in
our group also showed that other murine models of
lupus display impaired endothelium-dependent vasore-
laxation, a phenomenon associated with progression to
atherosclerosis in human systems (33). In pristane-
treated C57BL/6 mice, but not in pristane-treated
BALB/c mice, a similar decrease in endothelium-
dependent vasorelaxation was observed following expo-
Figure 3. Increased endothelial progenitor cell (EPC) differentiation and endothelium-dependent vasorelaxation in the absence of caspase 1. A,
Bone marrow (BM) was isolated from WT C57BL/6 mice or caspase 1–/– (Casp-1 –/–) C57BL/6 mice (left) or from WT BALB/c mice or caspase 1–/–
BALB/c mice (right), and EPCs were quantified by flow cytometry. Results are the number of EPCs/106 BM cells for each group. B, BM cells were
plated under proangiogenic conditions. After 7 days, the number of mature endothelial cells (ECs)/high-power (HP) field was quantified by
fluorescence microscopy. Left, WT C57BL/6 mice compared to caspase 1–/– C57BL/6 mice. Right, WT BALB/c mice compared to caspase 1–/–
BALB/c mice.   P  0.05;   P  0.001. In A and B, 5 WT C57BL/6 mice were injected with PBS and 8 were injected with pristane, 10 caspase
1–/– C57BL/6 mice were injected with PBS and 14 were injected with pristane, 7 WT BALB/c mice were injected with PBS and 14 were injected with
pristane, and 11 caspase 1–/– BALB/c mice were injected with PBS and 24 were injected with pristane. C, Shown are representative photomicrographs
of the EC cultures from BALB/c mice depicted in B. Bars  20 m. D, Endothelium-dependent vasorelaxation of aortic rings was quantified
following exposure of 80% contracted aortic rings to graded concentrations of acetylcholine (ACh).   P  0.05;   P  0.01;   P  0.001
versus WT mice. Bars show the mean  SEM. Phase  phase contrast; Ac-LDL  acetylated low-density lipoprotein; EC80  effective
concentration of phenylephrine for 80% maximal contraction (see Figure 1 for other definitions).
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sure to pristane. However, following exposure to PBS or
pristane, both BALB/c and C57BL/6 caspase 1–/– mice
displayed significant increases in endothelium-
dependent vasorelaxation when compared to WT mice
(Figure 3D). These results indicate that caspase 1 mod-
ulates the vasodilatory capacity of the endothelium,
independent of lupus phenotype or mouse strain.
Caspase 1 is required for the development of
immune complex glomerulonephritis in pristane-
induced lupus. As expected, pristane exposure resulted
in prominent immune complex deposition in the glom-
eruli of WT BALB/c mice. In contrast, caspase 1–/– mice
had significant decreases in glomerular immune complex
deposition (Figures 4A and B). Furthermore, lack of
caspase 1 protected BALB/c mice exposed to pristane
from glomerular inflammation (Figures 4C and D).
Decreases in immune complex deposition and renal
inflammation in caspase 1–/– mice correlated signifi-
cantly with decreases in titers of anti-dsDNA, anti-RNP,
and total IgG (not shown). While WT BALB/c mice
showed a trend toward increased albuminuria following
pristane exposure, caspase 1–/– mice did not have similar
increases after pristane exposure (Figure 4E). Similar
patterns were found when examining total protein-to-
creatinine ratios (not shown). Further, WT mice ex-
posed to pristane, but not caspase 1–/– mice exposed to
pristane, showed a trend toward increased serum IL-18
levels, and the serum concentration of IL-18 correlated
significantly with the severity of nephritis in WT mice
exposed to pristane (Figures 4F and G). These results
indicate that glomerular immune complex deposition
and renal inflammation are hampered in the absence of
Figure 4. Caspase 1 modulates immune complex deposition and glomerular activity scores in lupus-prone mice. A and B, Deposition of C3 (green)
and IgG (red) was quantified in kidneys obtained from WT BALB/c mice or caspase 1–/– (Casp-1 –/–) BALB/c mice following exposure to PBS or
pristane. Composite scores were averaged (A), and representative photomicrographs are shown (B). Each symbol represents an individual kidney.
There were 7 PBS-treated WT mice, 11 PBS-treated caspase 1–/– mice, 14 pristane-treated WT mice, and 23 pristane-treated caspase 1–/– mice.
Bars  20 m. C and D, Glomerular inflammation activity scores were determined on periodic acid–Schiff–stained, formalin-fixed kidney sections
from WT or caspase 1–/– mice exposed to PBS or pristane. Composite scores were averaged (C). Each symbol represents an individual kidney.
Representative photomicrographs (D) demonstrate enlarged, hypercellular glomeruli due to mesangial and endocapillary inflammation in
pristane-treated WT mice, but not in pristane-treated caspase 1–/– mice. There were 6 PBS-treated WT mice, 8 PBS-treated caspase 1–/– mice, 14
pristane-treated WT mice, and 19 pristane-treated caspase 1–/– mice. Bars  100 m. E, Microalbumin-to-creatinine (microalb/Cr) ratios were
determined in urine collected at the time of euthanasia. F, Levels of IL-18 in serum collected 5 months after PBS or pristane treatment were
determined by enzyme-linked immunosorbent assay. In E and F, there were 7 PBS-treated WT mice, 11 PBS-treated caspase 1–/– mice, 14
pristane-treated WT mice, and 23 pristane-treated caspase 1–/– mice. G, Linear regression of the IL-18 concentration versus the renal activity score
in pristane-treated WT mice (n  12) is shown. Bars show the mean  SEM.   P  0.05;   P  0.01;   P  0.001. IF 
immunofluorescence (see Figure 1 for other definitions).
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caspase 1 and that activation of IL-18 by caspase 1 may
be an important step in nephritis induction in this model.
DISCUSSION
The development of lupus is considered to be the
result of an aberrant interplay between innate and
adaptive immune responses. Recently, it has been pro-
posed that the inflammasome machinery is dysregulated
in lupus systems secondary to type I IFN, aberrant cell
death, and autoantibody-mediated effects (4,10–12,34).
The results presented here identify novel roles for
caspase 1, the central enzyme of the inflammasome, in
the pristane-induced model of lupus. Indeed, the ab-
sence of caspase 1 abrogated known hallmarks of murine
and human SLE, including autoantibody development,
type I IFN signatures, and renal inflammation.
There are several likely mechanisms by which
caspase 1 modulates lupus development. Serum levels
of IL-18 are elevated in SLE patients and have been
correlated with disease severity and lupus nephritis
(17,35,36), and in the MRL-Faslpr lupus model, a role
has been proposed for IL-18 in nephritis and skin
disease (37). IL-18 regulates IFN production (38), and
this may further modulate SLE development as IFN is
required for disease pathology (39). Up-regulation of
IL-1 and IL-18 transcripts in response to pristane was
not observed in caspase 1–/– mice, suggesting that
pristane may require caspase 1–dependent pathways to
induce these cytokines. Additionally, the severity of
nephritis correlated significantly with serum levels of
IL-18 in these mice, suggesting that caspase 1 activation
of IL-18 may play a pathogenic role in nephritis induc-
tion.
Despite the profound effect on lupus develop-
ment, lack of caspase 1 did not affect peritoneal inflam-
matory responses to pristane. Indeed, enhanced neutro-
phil recruitment was observed in the peritoneal cavity
of pristane-treated caspase 1–/– mice. Previously, the
recruitment of neutrophils following pristane exposure
was shown to be dependent on IL-1–mediated up-
regulation of CXCL5 (40). This cytokine is secreted in a
caspase 1–dependent manner and expressed on the cell
surface in a caspase 1–independent manner. Cell surface
IL-1 is increased following inhibition of caspase 1 (41);
thus, the paradoxical increase in neutrophils seen in
caspase 1–/– mice may be secondary to increased expres-
sion of surface IL-1. Additionally, increased surface
IL-1 in the absence of caspase 1 may explain the en-
hanced basal CXCL5 expression seen in caspase 1–/– mice.
The induction of accelerated cell death and ab-
errant uptake of apoptotic debris has been postulated as
a mechanism for lupus induction (27). Thus, lack of
caspase 1 may be protective against inflammatory re-
sponses initiated by apoptotic debris. Furthermore, in
addition to its role as activator of IL-1 and IL-18,
caspase 1 is also required for induction of inflammatory
cell death, which is also known as pyroptosis. While
traditionally activated by intracellular bacterial infec-
tion, caspase 1–dependent cell death may also be a
relevant physiologic cell death pathway (for review, see
ref. 42). Importantly, the phagocytosis of pyroptotic
debris may occur through similar “eat me” signals
employed by apoptotic cells (28). We hypothesize that
aberrant clearance of pyroptotic debris may also contrib-
ute to SLE pathogenesis. Our data show decreased
annexin V staining of inflammatory cells following
pristane exposure in caspase 1–/– mice, and annexin V
staining detects both apoptotic and pyroptotic debris
(28). As such, down-regulation of inflammatory cell
death following pristane exposure may decrease autoan-
tigen externalization, limit aberrant autoantibody forma-
tion, and decrease type I IFN synthesis. Future studies
should further test this hypothesis.
Caspase 1–/– mice exposed to pristane lack signif-
icant autoantibody development. Because autoreactive
B cells are activated by RNP autoantigens (43), the
abrogation of cell death pathways in caspase 1–/– mice
likely decreases B cell activation. Further, the profound
lack of chronic type I IFN up-regulation in caspase 1–/–
mice may have negative effects on B cells, as type I IFN
production is an important mediator of B cell activation
and class switching (44). Decreased IL-6 production in
caspase 1–/– mice may also contribute to lower autoan-
tibody titers, given that this cytokine has been reported
to synergize with type I IFN responses to induce matu-
ration of B cells into highly functional IgG-secreting
plasma cells (45), as well as to promote many other
proinflammatory responses.
The role of caspase 1 may relate not only to
autoantibody development in response to pristane but
also to downstream responses to immune complexes.
Recently, activation of the inflammasome via U1 small
nuclear RNP–anti-RNP complexes through TLR-7 stim-
ulation was described in human monocytes (11), and
similar responses occur in response to dsDNA–anti-
dsDNA antibody complexes (12). Further, caspase 1
activation is enhanced in SLE macrophages in response
to NETs (10). The associated cytokine generation fur-
ther enhances inflammatory responses and NET forma-
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tion, which can result in circulating immune complexes
capable of stimulating PDC activation and type I IFN
production (46). Thus, caspase 1 likely plays important
roles in both autoantibody generation and inflammatory
responses downstream of immune complexes.
With regard to the role of caspase 1 in SLE-
associated CV disease, lack of caspase 1 improved EPC
differentiation in the pristane-induced model of lupus.
This supports our previous observations that inhibition
of caspase 1 provides a vasculoprotective effect in hu-
man SLE (4). Others have demonstrated similar effects
on atherosclerosis development in apolipoprotein
E–null mice (30).
Endothelium-dependent vasorelaxation was in-
creased in the absence of caspase 1, independently of
mouse strain or lupus phenotype. The mechanisms
behind this enhanced relaxation in caspase 1–/– mice may
be secondary to a combination of decreased endothelial
damage and enhanced vascular repair. The inflam-
masome plays a role in response to cholesterol crystals
and generation of inflammatory responses in plaque
(29). Without active caspase 1, the negative effects of
vascular inflammation on the endothelium are likely
dampened. Further, type I IFNs and IL-18 have negative
effects on vascular repair (2,4,47). As caspase 1–/– mice
have repressed type I IFN responses and do not activate
IL-18, this may lead to improved EPC differentiation
and endothelial function. Additional studies are never-
theless required to further define how caspase 1 inhibi-
tion improves vascular function in murine and human
systems (47–49).
This study has some limitations. The experimen-
tal design addresses the role of caspase 1 in pristane-
induced lupus, but it does not provide information on
specific activation of the inflammasome in this model.
Additionally, recent observations on the caspase 1–/–
mouse have revealed that it contains a nonfunctional
caspase 11 gene (50). While not required for classic
inflammasome activation, caspase 11 may be important
for pathogen-induced inflammasome assembly and in
mediating pyroptosis in response to infection (50). Fur-
ther experiments should be performed to address the
role of caspase 11 specifically in the pristane-induced
model of lupus.
In summary, we have demonstrated a role of
caspase 1 in the development of murine lupus as its
absence is characterized by significant down-modulation
of autoantibody synthesis, type I IFN responses, glomer-
ulonephritis, and vascular dysfunction. These results
indicate the need to further explore the inflammasome
as a putative therapeutic target in this disease.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Drs. Kahlenberg and Kaplan had full
access to all of the data in the study and take responsibility for the
integrity of the data and the accuracy of the data analysis.
Study conception and design. Kahlenberg, Yalavarthi, Tsuji, Kaplan.
Acquisition of data. Kahlenberg, Yalavarthi, Zhao, Hodgin, Reed.
Analysis and interpretation of data. Kahlenberg, Yalavarthi, Zhao,
Hodgin, Kaplan.
REFERENCES
1. Ward MM. Premature morbidity from cardiovascular and cere-
brovascular diseases in women with systemic lupus erythematosus.
Arthritis Rheum 1999;42:338–46.
2. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ,
et al. Interferon- promotes abnormal vasculogenesis in lupus: a
potential pathway for premature atherosclerosis. Blood 2007;110:
2907–15.
3. Kirou K, Lee C, George S, Louca K, Peterson MG, Crow MK.
Activation of the interferon- pathway identifies a subgroup of
systemic lupus erythematosus patients with distinct serologic fea-
tures and active disease. Arthritis Rheum 2005;52:1491–503.
4. Kahlenberg JM, Thacker SG, Berthier CC, Cohen CD, Kretzler
M, Kaplan MJ. Inflammasome activation of IL-18 results in
endothelial progenitor cell dysfunction in systemic lupus erythem-
atosus. J Immunol 2011;187:6143–56.
5. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of
autoimmunity by pristane and other naturally occurring hydrocar-
bons. Trends Immunol 2009;30:455–64.
6. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J,
et al. TLR7-dependent and FcR-independent production of type
I interferon in experimental mouse lupus. J Exp Med 2008;205:
2995–3006.
7. Thibault D, Graham K, Lee L, Balboni I, Hertzog P, Utz P. Type
I interferon receptor controls B-cell expression of nucleic acid-
sensing Toll-like receptors and autoantibody production in a
murine model of lupus. Arthritis Res Ther 2009;11:R112.
8. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES, et al.
Type I interferon modulates monocyte recruitment and matura-
tion in chronic inflammation. Am J Pathol 2009;175:2023–33.
9. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health
and disease. Annu Rev Cell Dev Biol 2012;28:137–61.
10. Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neu-
trophil extracellular trap–associated protein activation of the
NLRP3 inflammasome is enhanced in lupus macrophages. J Im-
munol 2013;190:1217–26.
11. Shin MS, Kang Y, Lee N, Kim SH, Kang KS, Lazova R, et al.
U1-small nuclear ribonucleoprotein activates the NLRP3 inflam-
masome in human monocytes. J Immunol 2012;188:4769–75.
12. Shin MS, Kang Y, Lee N, Wahl ER, Kim SH, Kang KS, et al. Self
double-stranded (ds)DNA induces IL-1 production from human
monocytes by activating NLRP3 inflammasome in the presence of
anti-dsDNA antibodies. J Immunol 2013;190:1407–15.
13. Zhao W, Thacker SG, Hodgin JB, Zhang H, Wang JH, Park JL, et
al. The peroxisome proliferator-activated receptor  agonist pi-
oglitazone improves cardiometabolic risk and renal inflammation
in murine lupus. J Immunol 2009;183:2729–40.
14. Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C,
Nusse O. Mouse bone marrow contains large numbers of func-
tionally competent neutrophils. J Leukoc Biol 2004;75:604–11.
15. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R,
Lin AM, et al. Netting neutrophils induce endothelial damage,
infiltrate tissues, and expose immunostimulatory molecules in
systemic lupus erythematosus. J Immunol 2011;187:538–52.
CASPASE 1 IS REQUIRED FOR MURINE LUPUS 161
16. Liu X, Bao C, Hu D. Elevated interleukin-18 and skewed Th1:Th2
immune response in lupus nephritis. Rheumatol Int 2012;32:
223–9.
17. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F,
Silvestris F. Glomerular accumulation of plasmacytoid dendritic
cells in active lupus nephritis: role of interleukin-18. Arthritis
Rheum 2008;58:251–62.
18. Herman S, Kny A, Schorn C, Pfatschbacher J, Niederreiter B,
Herrmann M, et al. Cell death and cytokine production induced by
autoimmunogenic hydrocarbon oils. Autoimmunity 2012;45:
602–11.
19. Yang L, Feng D, Bi X, Stone RC, Barnes BJ. Monocytes from
irf5/ mice have an intrinsic defect in their response to pristane-
induced lupus. J Immunol 2012;189:3741–50.
20. Xu Y, Lee PY, Li Y, Liu C, Zhuang H, Han S, et al. Pleiotropic
IFN-dependent and -independent effects of IRF5 on the patho-
genesis of experimental lupus. J Immunol 2012;188:4113–21.
21. Weinstein JS, Delano MJ, Xu Y, Kelly-Scumpia KM, Nacionales
DC, Li Y, et al. Maintenance of anti-Sm/RNP autoantibody
production by plasma cells residing in ectopic lymphoid tissue and
bone marrow memory B cells. J Immunol 2013;190:3916–27.
22. Feng D, Yang L, Bi X, Stone RC, Patel P, Barnes BJ. Irf5-deficient
mice are protected from pristane-induced lupus via increased Th2
cytokines and altered IgG class switching. Eur J Immunol 2012;
42:1477–87.
23. Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA,
Green SL, et al. Network analysis of associations between serum
interferon- activity, autoantibodies, and clinical features in sys-
temic lupus erythematosus. Arthritis Rheum 2011;63:1044–53.
24. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner
S, et al. Deficiency of type I IFN receptor in lupus-prone New
Zealand mixed 2328 mice decreases dendritic cell numbers and
activation and protects from disease. J Immunol 2009;183:6021–9.
25. Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders
HJ, et al. Requirement of Toll-like receptor 7 for pristane-induced
production of autoantibodies and development of murine lupus
nephritis. Arthritis Rheum 2008;58:1107–15.
26. Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y,
Butfiloski E, et al. A novel type I IFN-producing cell subset in
murine lupus. J Immunol 2008;180:5101–8.
27. White S, Rosen A. Apoptosis in systemic lupus erythematosus.
Curr Opin Rheumatol 2003;15:557–62.
28. Wang Q, Imamura R, Motani K, Kushiyama H, Nagata S, Suda T.
Pyroptotic cells externalize eat-me and release find-me signals and
are efficiently engulfed by macrophages. Int Immunol 2013;25:
363–72.
29. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauern-
feind FG, et al. NLRP3 inflammasomes are required for athero-
genesis and activated by cholesterol crystals. Nature 2010;464:
1357–61.
30. Gage J, Hasu M, Thabet M, Whitman SC. Caspase-1 deficiency
decreases atherosclerosis in apolipoprotein E-null mice. Can
J Cardiol 2012;28:222–9.
31. Briasoulis A, Tousoulis D, Antoniades C, Papageorgiou N, Stefa-
nadis C. The role of endothelial progenitor cells in vascular repair
after arterial injury and atherosclerotic plaque development. Car-
diovasc Ther 2011;29:125–39.
32. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H,
et al. Number and migratory activity of circulating endothelial
progenitor cells inversely correlate with risk factors for coronary
artery disease. Circ Res 2001;89:E1–7.
33. Thacker SG, Duquaine D, Park J, Kaplan MJ. Lupus-prone New
Zealand Black/New Zealand White F1 mice display endothelial
dysfunction and abnormal phenotype and function of endothelial
progenitor cells. Lupus 2010;19:288–99.
34. Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S. AIM2 facilitates
the apoptotic DNA-induced systemic lupus erythematosus via
arbitrating macrophage functional maturation. J Clin Immunol
2013;33:925–37.
35. Hu D, Liu X, Chen S, Bao C. Expressions of IL-18 and its binding
protein in peripheral blood leukocytes and kidney tissues of lupus
nephritis patients. Clin Rheumatol 2010;29:717–21.
36. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F.
Up-regulation of IL-18 and predominance of a Th1 immune
response is a hallmark of lupus nephritis. Clin Exp Immunol
2004;138:171–8.
37. Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S,
Funauchi M, et al. Blockade of IL-18 receptor signaling delays the
onset of autoimmune disease in MRL-Faslpr mice. J Immunol
2004;173:5312–8.
38. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA.
Differences in signaling pathways by IL-1 and IL-18. Proc Natl
Acad Sci U S A 2004;101:8815–20.
39. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H,
Reeves WH. Interferon- is required for lupus nephritis in mice
treated with the hydrocarbon oil pristane. Kidney Int 2001;60:
2173–80.
40. Lee PY, Kumagai Y, Xu Y, Li Y, Barker T, Liu C, et al. IL-1
modulates neutrophil recruitment in chronic inflammation in-
duced by hydrocarbon oil. J Immunol 2011;186:1747–54.
41. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer
HD, Johansen P, Senti G, et al. Inflammasome activation and
IL-1 target IL-1 for secretion as opposed to surface expression.
Proc Natl Acad Sci U S A 2011;108:18055–60.
42. Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the
tip of the ICEberg? Cell Death Dis 2012;3:e338.
43. Green NM, Moody KS, Debatis M, Marshak-Rothstein A. Acti-
vation of autoreactive B cells by endogenous TLR7 and TLR3
RNA ligands. J Biol Chem 2012;287:39789–99.
44. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres
RM. Type I IFN enhances follicular B cell contribution to the T
cell–independent antibody response. J Exp Med 2010;207:
1485–500.
45. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V,
Banchereau J. Plasmacytoid dendritic cells induce plasma cell
differentiation through type I interferon and interleukin 6. Immu-
nity 2003;19:225–34.
46. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio
J, et al. Neutrophils activate plasmacytoid dendritic cells by
releasing self-DNA-peptide complexes in systemic lupus erythem-
atosus. Sci Transl Med 2011;3:73ra19.
47. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-
Giri A, et al. Type I interferons modulate vascular function, repair,
thrombosis, and plaque progression in murine models of lupus and
atherosclerosis. Arthritis Rheum 2012;64:2975–85.
48. Kahlenberg JM, Kaplan MJ. The interplay of inflammation and
cardiovascular disease in systemic lupus erythematosus. Arthritis
Res Ther 2011;13:203.
49. Niessner A, Weyand CM. Dendritic cells in atherosclerotic dis-
ease. Clin Immunol 2010;134:25–32.
50. Kayagaki N, Warming S, Lamkanfi M, Walle LV, Louie S, Dong
J, et al. Non-canonical inflammasome activation targets caspase-
11. Nature 2011;479:117–21.
162 KAHLENBERG ET AL
